Compare ONDS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONDS | ALKS |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.6B |
| IPO Year | N/A | 1991 |
| Metric | ONDS | ALKS |
|---|---|---|
| Price | $10.34 | $34.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $19.00 | ★ $42.85 |
| AVG Volume (30 Days) | ★ 107.2M | 2.2M |
| Earning Date | 03-11-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.44 |
| EPS | N/A | ★ 2.02 |
| Revenue | $24,748,922.00 | ★ $1,521,338,000.00 |
| Revenue This Year | $549.77 | N/A |
| Revenue Next Year | $276.13 | $23.22 |
| P/E Ratio | ★ N/A | $17.34 |
| Revenue Growth | ★ 208.40 | 1.08 |
| 52 Week Low | $0.57 | $25.17 |
| 52 Week High | $15.28 | $36.45 |
| Indicator | ONDS | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 64.06 |
| Support Level | $8.34 | $33.35 |
| Resistance Level | $11.40 | $35.02 |
| Average True Range (ATR) | 1.29 | 1.18 |
| MACD | -0.40 | 0.01 |
| Stochastic Oscillator | 32.94 | 82.98 |
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.